Wang, Keshi
BridgeBio Oncology Therapeutics (United States)
5 papers on CoChatORCID 0009-0000-7576-6447
Most cited papers
- Verified
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 393
- Verified
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research
Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment
Cited by 336
- Verified
3-[(1 S ,2 S ,3 R )-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma
Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry
Cancer, Hypoxia, and MetabolismHeterocyclic Compound Synthesis and Bioactivity
Cited by 220
- Verified
A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Wang, K., Wallace, E., Josey, J. A., et al. (2016) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 7
- Verified
Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism
Beltran, P., Dhirendra, S., Xu, R., Chen, M., Czyzyk, D., Donovan, S., Feng, S., Feng, C., Fu, L., Lightstone, F., et al. (2024) · Cancer Research
PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free